The American Food and Drug Administration recently approved a booster for the Pfizer and BioNTech covid-19 vaccine for people who are 65 years and over as well as some high-risk American citizens. A second dose has been approved for enhancement of the vaccine activity. As time progresses, the immune response exhibited by the first and second dose could lower and thus need for a booster shot.
The booster shot is primarily for older people and those that have other complications. Those that are susceptible will also be included in this program. The principal aim of this shot is to provide a long-term defense against the virus. However, is was no sufficient proof to allow the administration of the booster shots for the young people who have already received the other doses. The various groups, including the American Centers for disease control, are undertaking more research to confirm the efficiency of the booster vaccine. The FDA has modified the use of the Pfizer-BioNTech COVID-19 vaccine as a single booster dose.